Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented at 10:15 a.m. CT by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.
Coming up: Investigators will review latest data from VERTIS-CV trial of SGLT2 inhibitor ertugliflozin
